{
    "nct_id": "NCT05624554",
    "official_title": "A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations",
    "inclusion_criteria": "* Confirmed diagnosis of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) and active disease clearly documented to have a need to initiate therapy\n* Has previously untreated CLL/SLL participants without tumor protein 53 (TP53) aberrations and documented 11q status and immunoglobulin heavy chain gene (IGHV) mutational status\n* The ability to swallow and retain oral medication\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection\n* Gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy\n* History of severe bleeding disorders\n* Not adequately recovered from major surgery or has ongoing surgical complications",
    "miscellaneous_criteria": "The main inclusion and exclusion criteria include but are not limited to the following:"
}